Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituxima... скачать в хорошем качестве

Vitamin D in patients with low tumour-burden indolent non-Hodgkin lymphoma treated with rituxima...

Dr Jonathan Friedberg speaks to ecancer about the results from the phase III double blind, randomised Ilyad trial presented at ASH 2023. The trial evaluated a vitamin D intervention in patients with low tumour-burden indolent non-Hodgkin lymphoma along with rituximab therapy. He explains that all patients received rituximab and were randomised so that 2/3s received vitamin D and 1/3 received a placebo. Dr Friedberg reports that, from an efficacy perspective, the study was a negative trial and no benefit was seen with the addition of vitamin D to the rituximab. This was the case throughout the different subtypes. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php